Arrivent Biopharma, Inc. (NASDAQ: AVBP) has announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company will present preclinical findings for its EGFR inhibitor firmonertinib and data on ARR-002, a novel dual-target muc16/napi2b tetravalent antibody drug conjugate (ADC).
The preclinical findings for firmonertinib highlight its unique structural features, demonstrating high potency inhibition of EGFR mutations and strong anti-tumor activity across multiple in vitro and in vivo models. Firmonertinib, which is approved in China for frontline classical and second-line exon20ins EGFR mutant non-small cell lung cancer (NSCLC), has shown early clinical evidence supporting activity against uncommon mutations, including ex20ins and pacc variants.
On the other hand, ARR-002, a novel muc16/napi2b dual-target tetravalent ADC, has demonstrated effective binding to individual targets, simultaneous engagement of both targets, and enhanced internalization compared to single-target ADC controls. The preclinical data also showed superior in vivo efficacy in the ovcar-3 xenograft model and a favorable tolerability profile in cynomolgus monkeys.
Firmonertinib, an oral, mutation-selective EGFR inhibitor, was approved in China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or l858r mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR t790m mutation. It was also granted U.S. FDA breakthrough therapy designation and orphan drug designation for the treatment of NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations. Currently, firmonertinib is being studied in a global phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global phase 3 study in first-line NSCLC patients with EGFR pacc mutations (ALPACCA).
ARR-002, also known as AV-P138-ADC, is a first-in-class, mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NAPI2B) dual-target, tetravalent ADC, with site-specific conjugation to VCMMAE at a drug-to-antibody ratio (DAR) of 4. Both these cell surface antigens are expressed in ovarian and endometrial cancers with limited expression in normal tissues, making them ideal co-targets.
Arrivent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization. The market has reacted to these announcements by moving the company's shares -4.75% to a price of $20.86. For the full picture, make sure to review ArriVent BioPharma's 8-K report.
